Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Farmsintez ao Produces APIs & hospital drugs for oncology & specialty diseases; offers contract services.	Russian Federation	LIFE
FATE THERAPEUTICS INC Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.	United States of America	FATE
FENNEC PHARMACEUTICALS INC. Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.	United States of America	FENC
FibroBiologics, Inc. Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.	United States of America	FBLG
FIBROGEN INC Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.	United States of America	FGEN
Fine Foods & Pharmaceuticals Ntm Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.	Italy	FF
Flora Growth Corp. A diversified firm in pharma distribution, plant-based wellness, and digital assets.	United States of America	FLGC
Foghorn Therapeutics Inc. Pioneering medicines targeting the chromatin regulatory system to treat genetically defined cancers.	United States of America	FHTX
Formycon AG Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.	Germany	FYB
Fortress Biotech, Inc. Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.	United States of America	FBIO